Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives

Seminars in Liver Disease

Volumn 19, Issue 3, 1999, Pages 253-262

  Chen, Pei Jer ^b   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

Chronic hepatitis B; Cirrhosis; Genetic alterations; Hepatitis B virus; Hepatocellular carcinoma; Prevention

Indexed keywords

BETA CATENIN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PROTEIN P53;

ARTICLE; CANCER RISK; CHROMOSOME ABERRATION; CHRONIC HEPATITIS; DNA HYBRIDIZATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOSITY; HUMAN; IMMUNIZATION; LIVER CELL CARCINOMA; MOLECULAR GENETICS; PRIORITY JOURNAL; RISK FACTOR;

EID: 84984538753     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007115     Document Type: Article

References (61)

1. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: K Okuda, E Tabor, eds. Liver Cancer. New York: Churchill Livingstone, 1997, pp 13-28
2. El-Serag HB, Mason AC. Rising risk of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750
3. Beasley RP. Hepatitis B virus - the major etiology for hepatocellular carcinoma. Cancer 1988;61:1942-1956
4. Snyder RL, Tyler G, Summers J. Chronic hepatitis and hepatocellular carcinoma associated with woodchuck hepatitis virus. Am J Pathol 1982;107:422-425
5. Di Bisceglie AM, Carithers, Gores GJ. Hepatocellular carcinoma. Hepatology 1998;28:1161-1165
6. Chen CJ, Yu MH, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-30
7. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors associated for hepatocellular carcinoma in patients with chronic liver diseases. N Engl J Med 1993;328:1797-1801
8. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92
9. Bresailer RS, Kim YS. Malignant neoplasms of the large intestine. In: MH Sleisenger, JS Fordtran, eds. Gastrointestinal Disease. Philadelphia: W.B. Saunders, 1993, pp 1447-1493
10. Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroentrology 1985;80:318-327
11. Dobbins WO. Current status of the precancerous lesion in ulcerative colitis. Gastroenterology 1977;73:1431-1437
12. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Presinger AC, Leppert M. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-532
13. Tabor E. Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 1994;42:257-265
14. La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851
15. He TC, Sparks AB, Pago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512
16. Yamada T, De Souza AT, Finkelstein S, Jirtel RL. Loss of the gene encoding mannose-6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997;94:10351-10355
17. Chen HL, Chen YC, Chen DS. Chromosome Ip aberrations are frequent in primary hepatocellular carcinoma. Cancer Genet Cytogenet 1996;45:102-106
18. Kallioniemi A, Kallioniemi O-P, Sudar D, et al. Comparative genomic hybridization for molecular genetic analysis of solid tumors. Science 1992;258:818-821
19. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353
20. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-1947
21. Collins FS, Patrinos A, Jordan E. et al. New goals for the U.S. human genome project: 1998-2003. Science 1998;282:682-689
22. Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Gene Chromos Cancer 1997;18: 59-65
23. Wong N, Lai P, Lee WW, et al. Assessment of genetic changes in the hepatocellular carcinoma by comparative genomic hybridization analysis. Am J Pathol 1999;154:37-43
24. Boige V, Laurent-Puig P, Fouchet P, et al. Concerted non-syntenic allelic losses in hyperploid hepatocelluar carcinoma as determined by high-resolution allelotype. Cancer Res 1997;57:2986-2990
25. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-2933
26. Nishida N, Fukuda Y, Kokuryu H, et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992; 51:862-868
27. Aihara T, Nogichi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of heaptocellular carcinoma. Gastroenterology 1996;111:455-461
28. Macdonald GA, Greenson JK, Saito K, Cgerian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998;28:90-97
29. Schrock E, du Manoir S, Veldamn T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273:494-497
30. Matsubara K, Tokina T. Integration of hepatitis B virus DNA and its implication for hepatocarcinogenesis. Mol Biol Med 1990; 7:243-260
31. Gotllob K, Fulco M, Levero M, Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 1998;273:33347-33353
32. Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cell. J Biol Chem 1998;273:381-385
33. Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997;94:24707-24712
34. Araki K, Miyazaki JI, Hino O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989;86:207-211
35. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-350
36. Lazutka JR. Genetic toxicity of cytokines. Mutat Res 1996; 361:95-105
37. Hagen TM, Wehr C, Huang SN, et al. Extensive oxidative DNA damages in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 1994;91:12808-12812
38. Chu CM, Yeh CT, Sheen IS, Liaw YF. Subcellular localization of hepatitis B antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology 1995;109:1926-1932
39. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995;22:983-993
40. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998;28:953-958
41. Tsuda H, Hirohashi S, Shimamoto Y, Terada, Hagesawa M. Clonal origin of atypical adenomatous hyperplasia and clonal identity with hepatocellular carcinoma. Gastroenterology 1998; 95:1664-1666
42. Shiratoti Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C viral infection in Japan. Hepatology 1995;22:1027-1033
43. Chang MH, Chen DS, Hsu HY, Lee CH. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989;64:2377-2380
44. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-908
45. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-1859
46. Nicoll A, Locarrini S. Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997; 12:843-854
47. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-323
48. International Interferon-Alpha Hepatocellular Carcinoma Study Group. Effects of Interferon alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective study. Lancet 1998; 351:1535-1539
49. Thun MU. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996;25:333-348
50. Muto Y, Moriwaki H, Nonomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334: 1561-1567
51. Yeh, SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma. Gastroenterology 1996;110:184-192
52. DeRisis J, Penl L, Brown PQ, et al. Use of a cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996;14:457-460
53. Terasaki S, Kaneko S, Kobayashi K, Nonomura A, Nakamura Y. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenter ology 1998;115:1216-1222
54. Hsu HC, Wu TT, Wu MZ, et al. Tumor invasiveness and prognosis in resected hepatocellular carcinoma: clinical and pathogenic implication. Cancer 1988;61:2095-2099
55. Orsolini P, Belloni C, Klersy C, et al. Anti-HBV neonatal immunization with recombinant vaccine. Part I. Critical appraisal for a long-lived antibody course. Vaccine 1995;13: 551-554
56. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-1673
57. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-975
58. Ferrari CA, Penna A, Bertolli A, et al. Cellular immune response to hepatitis B virus-encoded protein in acute and chronic hepatitis B virus infection. J Immunol 1990;145:3442-3449
59. Davis HL, Shirmbeck R, Reimann J, Whalen RG. DNA-mediated immunization in mice induce a potent MHC-class I restricted cytotoxic T lymphocytes response to the hepatitis B envelope protein. Hum Gene Ther 1995;6:1447-1455
60. Sallberg M, Highes J, Javada A, et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998;9: 1719-1729
61. Rollier C, Sunyach C, Barraud N, et al. Trepo C, Cova L. Protective and therapeutic effects of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999; 116:658-665